Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

aTYR Pharma INC

NASDAQ: ATYR · Life Sciences · 7 alerts · CIK 1339970

Share price
$5.24Close, Nov 16
Market cap
$13.4M
Shares outstanding
2.55MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All aTYR Pharma INC filings on SEC EDGAR ↗

4:02 PM ET 8-K
Nasdaq/NYSE Compliance Notice

aTYR Pharma Nasdaq/NYSE Compliance Notice

aTyr Pharma has regained compliance with Nasdaq's minimum bid price requirement after its common stock closed at or above $1.00 per share for 10 consecutive business days. The company had previously been under a deficiency notice since December 2025 and was granted an extension until November 30, 2026, to meet the standard. As of this filing, the company has no outstanding deficiency notices from Nasdaq.

Counterparty
Nasdaq
4:09 PM ET 8-K
Capital Raise

aTYR Pharma Capital Raise

aTyr Pharma, Inc. filed a prospectus supplement to establish an at-the-market (ATM) offering program for the sale of up to $79,994,251 of its common stock. The sales will be conducted through Jefferies LLC as the sales agent under an existing Open Market Sale Agreement. This filing allows the company to raise equity capital from time to time at prevailing market prices.

Counterparty
Jefferies LLC
6:05 AM ET 10-Q
Financial Results

aTYR Pharma Q3 2026 Results: Net Loss of $18.3M, Loss Narrows

For the nine months ended September 30, 2026, aTyr Pharma reported a consolidated net loss of $39.4 million, an improvement from the $60.2 million loss in the prior year period. Total assets decreased to $59.8 million from $93.0 million at year-end 2025, primarily due to a reduction in available-for-sale investments used to fund operations.

Key figure
Net loss $18.3M
4:08 PM ET 8-K
Financial Results

aTYR Pharma Financial Results

aTyr Pharma reported third quarter 2026 financial results, ending the period with $50.3 million in cash and investments, providing a runway into late 2028. The company reached alignment with the FDA on a Phase 3 study protocol for efzofitimod in pulmonary sarcoidosis and is prioritizing strategic partnerships to advance the program.

“During the last quarter we reached alignment with the U.S. Food and Drug Administration (FDA) on the protocol for a Phase 3 study of our lead therapeutic candidate, efzofitimod, in pulmonary sarcoidosis patients with restrictive lung disease, a major form of interstitial lung disease (ILD) with a high unmet medical need. We believe the efzofitimod program is well-positioned, considering the late-stage development status in an indication with a multi-billion-dollar global market opportunity, and have determined that at this time the best way for us to advance efzofitimod is to prioritize strategic partnerships.”

Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer
9:03 AM ET 8-K
Reverse Stock Split

aTYR Pharma Reverse Stock Split

aTyr Pharma filed a Certificate of Amendment to effect a 1-for-40 reverse stock split of its common stock, effective October 28, 2026. The split will reduce the number of outstanding shares from approximately 100.5 million to 2.5 million to meet exchange requirements. Trading on a split-adjusted basis will begin on The Nasdaq Capital Market on October 29, 2026.

4:03 PM ET 8-K
Reverse Stock Split

aTYR Pharma Reverse Stock Split

aTyr Pharma stockholders approved a proposal at a special meeting to authorize the Board of Directors to effect a reverse stock split of the company's common stock. The approved ratio range is between 1-for-10 and 1-for-50, with the final ratio to be determined at the Board's discretion.

7:53 AM ET 8-K
Business Update

aTYR Pharma Business Update

aTyr Pharma reached alignment with the FDA on the protocol for a new Phase 3 study of efzofitimod in patients with chronic, symptomatic pulmonary sarcoidosis with restrictive lung disease. The global study is expected to enroll approximately 372 patients and initiate study-related activities in the fourth quarter of 2026.

Counterparty
FDA
Term
54 weeks

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.